GLP-1s and pregnancy: Ozempic, Wegovy, Mounjaro and Zepbound before and during

Reviewed 14 sourcesPublished by PepVault

Ozempic, Wegovy, Mounjaro and Zepbound in pregnancy: each label's stop-before line, the pill warning, breastfeeding, wash-out times and what 2026 studies found.

Woman in a mustard linen dress walks a gravel path among palms and tree ferns
Last reviewed
Sources
14
Questions
7
Compounds
2

The short answer

The Ozempic and Wegovy labels say to stop semaglutide at least 2 months before a planned pregnancy, because it lingers in the blood for 5 to 7 weeks. The Mounjaro and Zepbound labels set no such interval: tirzepatide's half-life is about 5 days, and Zepbound's label says to stop once a pregnancy is known. US obstetricians advise 1 to 2 months for any GLP-1. Your prescriber sets the date.

Every number checked at its primary source · · 14 sources · How we research

Evidence: FDA labels (DailyMed) for the four brands, observational cohort studies and one meta-analysis of pregnancies exposed to GLP-1s, two milk studies (one on each label for tirzepatide) and animal reproduction studies on the labels; no randomised trial in pregnancy exists, and pregnant women were excluded from the drugs' trials.

Woman in a mustard linen dress walks a gravel path among palms and tree ferns

When do you stop Ozempic, Wegovy, Mounjaro or Zepbound before getting pregnant?

The four labels do not say the same thing, and most pages that answer this question merge them into one "two months" rule. Only the two semaglutide labels set a stop date before a planned pregnancy. The two tirzepatide labels have no interval at all; what they add instead is a warning about the birth-control pill. Here is each label's own line, from the versions on DailyMed as of November 20, 20261234:

LabelBefore a planned pregnancyOnce pregnantBreastfeedingThe pill
Ozempic (semaglutide, type 2 diabetes)Stop at least 2 months before, "due to the long washout period"1Use only if the potential benefit justifies the potential risk to the fetus1No human data; found in rat milk at 3 to 12 times lower levels than in the mother's blood1Tested with ethinyl estradiol and levonorgestrel; no contraception step on the label1
Wegovy (semaglutide, weight)Stop at least 2 months before, "to account for the long half-life" (for liver disease, MASH, only where the risk outweighs the benefit)2Stop if it is used for weight or heart-risk reduction; for MASH, only if the benefit justifies the risk; a pregnancy registry exists2Tablets: not recommended; injection: no human data2No clinically significant change2
Mounjaro (tirzepatide, type 2 diabetes)No interval given3Use only if the potential benefit justifies the potential risk to the fetus3Undetectable or low in a study of 11 women3Switch to a non-oral method, or add a barrier method, for 4 weeks after starting and after each dose increase3
Zepbound (tirzepatide, weight and sleep apnea)No interval given4Stop when a pregnancy is recognized; a pregnancy registry exists4Undetectable or low in a study of 11 women4The same 4-week rule4

The split follows what each drug is for. Wegovy and Zepbound treat weight, and both labels say plainly that "weight loss offers no benefit to a pregnant patient and may cause fetal harm", so the drug stops when the pregnancy is known24; Wegovy's label makes one exception, for MASH, a liver disease it also treats2. Ozempic and Mounjaro treat type 2 diabetes, and uncontrolled blood sugar in pregnancy carries its own risks to mother and baby, so those labels leave the choice to a weighing of benefit and risk, which is the prescriber's to make13.

A smiling woman in a blue top leaning on her kitchen counter with her phone and a notebook

PepVault for iPhone

Keep your protocol in PepVault

PepVault's dose log keeps the date and amount of every shot you log, so the day of your last dose is on record when your prescriber asks how long it has been.

Download on the App Store

7 days free on the yearly plan for new subscribers.

How long does each drug take to leave your body?

The stop date comes from the half-life, the time it takes for half of the drug in the blood to be cleared. After one half-life half remains, after two a quarter, and after five about 3% (one thirty-second). Semaglutide's half-life is about a week; tirzepatide's is about 5 days, or 5 to 6 days in people with obesity1234.

DrugHalf-life on the labelFive half-livesWhat the label says
OzempicAbout 1 weekAbout 5 weeksPresent in the circulation for about 5 weeks after the last dose1
WegovyAbout 1 weekAbout 5 weeksAbout 5 to 7 weeks after the last 2.4 mg or 7.2 mg shot or 25 mg tablet2
MounjaroAbout 5 daysAbout 25 daysNo wash-out time stated3
ZepboundAbout 5 to 6 days25 to 30 daysNo wash-out time stated4

So the semaglutide labels' 2 months is the 5 to 7 weeks of wash-out with a margin added. Tirzepatide is mostly gone in about four weeks, and no label turns that into a rule. The US obstetricians' college (ACOG) does, for every GLP-1: its October 2026 advisory tells clinicians to consider stopping 1 to 2 months before conception, and if a pregnancy starts on one, to advise against using it for the rest of the pregnancy14. Which date applies to you is your prescriber's call.

Try it

How Semaglutide builds up

An estimate from a half-life of about 6.9 days, one dose a week for four weeks. The shape of the level, not a measurement.

Try your own scheduleSemaglutide in the library

PepVault's dose log keeps the date and amount of every shot you log, so the day of your last dose is on record when your prescriber asks how long it has been. Log it in PepVault

Can you get pregnant on a GLP-1, and does it affect the pill?

Yes, and sometimes more easily than before. Extra body weight lowers fertility, and a 2025 review concludes that weight-loss medicines support spontaneous conception and the response to ovulation treatment, while live-birth data are still missing13. That fits the "Ozempic babies" of the headlines: weight comes off, ovulation returns, and a pregnancy follows.

The pill is the other half. Tirzepatide slows how fast the stomach empties, most after the first dose, and that can lower how much of a birth-control pill is absorbed. Both tirzepatide labels say to switch to a non-oral method, or add a barrier method such as condoms, for the 4 weeks after starting and the 4 weeks after each dose increase34. Patches, rings, implants, injections and IUDs do not go through the stomach. The semaglutide labels list no such step12. The measured drop in pill hormones, and what it means for hormone therapy, is in our guide to GLP-1s and menopause.

PepVault logs the dose with every shot, so the day each step-up began, where the label's 4 weeks start, stays on record. Log it in PepVault

What if you find out you're pregnant while taking one?

Most exposures happen this way: a dose in the weeks before a pregnancy test turns positive. The studies of those pregnancies are, so far, reassuring on birth defects. Each compares exposed pregnancies with similar women on other treatment, and none is a randomised trial:

StudyWhoMajor birth defects
Cesta 2024, Nordic countries, US and Israel5938 infants exposed around conception, mothers with type 2 diabetes8.3% vs 7.8% on insulin; adjusted risk ratio 0.95 (0.72 to 1.26)
Dao 2024, six teratology services6168 pregnancies exposed in the first trimester2.6% vs 2.3% with diabetes on other drugs and 3.9% with overweight
Brown 2026, US claims73,572 pregnancies with a GLP-1 fill in the 90 days before the last period; birth defects counted in 1,499 infantsContinuing vs stopping: ratio 1.21 (0.83 to 1.82), too imprecise to rule a difference in or out
Uysal 2026, meta-analysis of 7 cohorts8Over 40,000 exposed pregnanciesFirst-trimester odds ratio 1.39 (0.73 to 2.65), not significant; one unadjusted signal for urinary-tract defects, put down to confounding by the authors

In Brown's study, pregnancies that ended without a live birth were 29.7% with continued fills and 27.1% without, a risk ratio of 1.09 (0.98 to 1.23)7. The meta-analysis found no rise in stillbirth, miscarriage, small babies or preterm birth, and rated its own certainty as low8. The warnings on the labels come from animals: in rats and rabbits, and for semaglutide in monkeys, fetal harm appeared at exposures near human ones, alongside the drugs' effects on the mothers' weight and food intake13. Those are animal results, and they are why the labels say what they say.

Wegovy and Zepbound each run a pregnancy registry, which collects outcomes from exposed pregnancies; the labels ask patients and clinicians to report to it24.

When to get help A positive test while on any of these four is a reason to call your prescriber or obstetrician that week, and anyone taking one for diabetes should ask before stopping, since blood sugar control matters in pregnancy too.

Does stopping before pregnancy change how the pregnancy goes?

It can, and this is the newest finding. A 2025 study at a US academic health system matched 448 pregnancies after a GLP-1 that was stopped before or early in pregnancy with 1,344 similar pregnancies without one9. The exposed women gained more weight and had more of the complications that extra gain brings:

OutcomeStopped a GLP-1Never on one
Weight gained in pregnancy13.7 kg (30 lb)10.5 kg (23 lb)
More than the recommended gain65%49%
Preterm birth17%13%
Gestational diabetes20%15%
High blood pressure in pregnancy46%36%

A 2026 study of semaglutide in a national US records database points at the cause. Women who stopped before pregnancy and women whose use ran into pregnancy had similar raised risks of excess weight gain and gestational diabetes, with no significant difference between the two groups, which the authors read as a rebound after stopping, not an effect of the drug on the baby10. A Danish nationwide study of 529 exposed pregnancies found more preterm births only among women taking a GLP-1 for diabetes, not for weight11. The Wegovy and Zepbound labels add that a healthy weight gain is recommended in every pregnancy, including with obesity24. A plan for the months after the last dose, food and movement, is worth making before the stop date.

Commonly reported: hunger and food noise coming back within a few weeks of the last shot, surprise pregnancies after the weight came off, and trouble telling early pregnancy nausea from the drug's.

Can you take a GLP-1 while breastfeeding?

Every label leaves it to a weighing of benefit and risk, with one firm exception: the Wegovy tablets are not recommended while breastfeeding2. They carry SNAC, an absorption helper that does pass into milk, and babies may clear it slowly; the label points to the injection, which has no SNAC, as the alternative2.

  • Tirzepatide: in a study of 11 women given one 5 mg dose, 164 of 171 milk samples had none detectable, and the total found over 28 days was under 0.02% of the mother's dose34.
  • Injected semaglutide: the label has no human data12. In milk samples from 8 women, it was not detected at all; the authors' worst case put the baby's dose at 1.26% of the mother's, against the usual 10% threshold12.
  • Both: no data yet on effects on the baby or on milk supply13.

Whether and when to restart after birth is a decision for you and your prescriber.

What should you ask your prescriber?

  • Which date should my last dose be, given the drug and dose I am on?
  • If I take the pill and start or step up tirzepatide, what do I use for the 4 weeks after?
  • If I take it for diabetes, what replaces it before and during pregnancy?
  • What is my plan for weight, food and blood sugar between the last dose and the birth?
  • Can I restart while breastfeeding, and in which form?

For what happens to appetite and weight after the last dose, read our guide to stopping a GLP-1 next.

Track it in the app

Sources

  1. Novo Nordisk. OZEMPIC (semaglutide) injection, prescribing information (DailyMed, SPL version 20, Jun 10, 2026): sections 8.1, 8.2, 8.3 and 12.3. dailymed.nlm.nih.gov
  2. Novo Nordisk. WEGOVY (semaglutide) injection and tablets, prescribing information (DailyMed, SPL version 19, revised 06/2026): sections 8.1, 8.2, 8.3 and 12.3. dailymed.nlm.nih.gov
  3. Eli Lilly and Company. MOUNJARO (tirzepatide) injection, prescribing information (DailyMed, SPL version 40, Sep 2, 2026): sections 8.1, 8.2, 8.3 and 12.3. dailymed.nlm.nih.gov
  4. Eli Lilly and Company. ZEPBOUND (tirzepatide) injection, prescribing information (DailyMed, SPL version 40, revised 08/2026): sections 8.1, 8.2, 8.3 and 12.3. dailymed.nlm.nih.gov
  5. Cesta CE, Rotem R, Bateman BT, et al. Safety of GLP-1 receptor agonists and other second-line antidiabetics in early pregnancy. JAMA Intern Med. 2024;184(2):144-152. PubMed 38079178
  6. Dao K, Shechtman S, Weber-Schoendorfer C, et al. Use of GLP1 receptor agonists in early pregnancy and reproductive safety: a multicentre, observational, prospective cohort study based on the databases of six Teratology Information Services. BMJ Open. 2024;14(4):e083550. PubMed 38663923
  7. Brown JP, Huybrechts KF, Straub L, et al. Continuing glucagon-like peptide-1 receptor agonists into the first trimester of pregnancy and pregnancy outcomes: a target trial emulation study using claims information. Ann Intern Med. 2026;179(7):929-937. PubMed 42258827
  8. Uysal N, Horoz E, Gungor M, et al. Pregnancy outcomes following maternal GLP-1 receptor agonist exposure: a systematic review and meta-analysis. Sci Rep. 2026 (online ahead of print). PubMed 42420519
  9. Maya J, Pant D, Fu Y, et al. Gestational weight gain and pregnancy outcomes after GLP-1 receptor agonist discontinuation. JAMA. 2025;334(24):2186-2196. PubMed 41284263
  10. Yu Y, Li X, Groth SW, et al. Gestational weight gain and pregnancy outcomes after semaglutide exposure. Obstet Gynecol. 2026;148(2):229-237. PubMed 42208070
  11. Hviid KVR, Banasik K, Mortensen LH, et al. Periconceptional GLP-1 receptor agonist exposure and obstetric outcomes: a Danish nationwide cohort study. Hum Reprod Open. 2026;2026(2):hoag015. PubMed 41852577
  12. Diab H, Fuquay T, Datta P, et al. Subcutaneous semaglutide during breastfeeding: infant safety regarding drug transfer into human milk. Nutrients. 2024;16(17):2886. PubMed 39275201
  13. Duah J, Seifer DB. Medical therapy to treat obesity and optimize fertility in women of reproductive age: a narrative review. Reprod Biol Endocrinol. 2025;23(1):2. PubMed 39762910
  14. American College of Obstetricians and Gynecologists. Use of glucagon-like peptide-1 receptor agonists in pregnancy and lactation. Practice Advisory, October 2026. acog.org

Newsletter · Weekly

The weekly peptide briefing.

New guides, the week’s peptide news, one tool. Free, one email a week, unsubscribe anytime.

We’ll email you a link to confirm. Your address is used for the briefing only. Privacy

PepVault for iPhone

Keep your protocol in PepVault

Log every dose, track every vial, and see your protocol come together.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Explore the live demo